Ageing, oestrogen, platelets and thrombotic risk.
1. Adverse thrombotic cardiovascular events increase in women coincident with the onset of menopause. 2. Age past menopause may be an important variable in defining the benefit/risk of hormone treatments. 3. Few studies have examined hormonal status as a variable of ageing using a polygenomic approach of both humoral and cellular components of the coagulation system. 4. Longitudinal studies of a global set of platelet functions that define procoagulant activity (i.e. adhesion, aggregation, secretion and thrombin production) in individuals with documented hormonal status are needed to better understand how hormonal changes associated with ageing impact thrombotic risk.
Miller
Virginia M
VM
Department of Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. miller.virginia@mayo.edu
Jayachandran
Muthuvel
M
Owen
Whyte G
WG
D000367:Age Factors; D000375:Aging / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D001792:Blood Platelets / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology* / Q000235:genetics / Q000378:metabolism; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D018384:Oxidative Stress; D015539:Platelet Activation; D017698:Postmenopause / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism*; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood / Q000150:complications* / Q000235:genetics / Q000378:metabolism
D004967:Estrogens; D011960:Receptors, Estrogen